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Abstract
Background: The results of cytogenetic investigations on unbalanced chromosome anomalies, both constitutional
and acquired, were largely improved by comparative genomic hybridization on microarray (a-CGH), but in
mosaicism the ability of a-CGH to reliably detect imbalances is not yet well established. This problem of sensitivity
is even more relevant in acquired mosaicism in neoplastic diseases, where cells carrying acquired imbalances
coexist with normal cells, in particular when the proportion of abnormal cells may be low.
We constructed a synthetic mosaicism by mixing the DNA of three patients carrying altogether seven chromosome
imbalances with normal sex-matched DNA. Dilutions were prepared mimicking 5%, 6%, 7%, 8%, 10% and 15%
levels of mosaicism. Oligomer-based a-CGH (244 K whole-genome system) was applied on the patients’ DNA and
customized slides designed around the regions of imbalance were used for the synthetic mosaics.
Results and conclusions: The a-CGH on the synthetic mosaics proved to be able to detect as low as 8%
abnormal cells in the tissue examined. Although in our experiment some regions of imbalances escaped to be
revealed at this level, and were detected only at 10-15% level, it should be remarked that these ones were the
smallest analyzed, and that the imbalances recurrent as clonal anomalies in cancer and leukaemia are similar in size
to those revealed at 8% level.
Introduction
The development in recent years of the microarray-
based comparative genomic hybridization (a-CGH) to
investigate unbalanced chromosome anomalies, both
constitutional and acquired, has largely changed and
improved cytogenetic investigations. Examples of appli-
cation of a-CGH which revealed to be instrumental in
reaching novel acquisitions are the following. Chromo-
some imbalances were revealed in 28 out of 140 (20%)
patients with normal karyotype associated with mental
disability and congenital malformations, 17 de novo and
7 inherited from a parent [1]. In a cohort of 27 patients,
with an apparently balanced reciprocal translocation and
an abnormal phenotype, the results of a-CGH showed
chromosome imbalances in 11 of them [2]. A review of
a large cohort of similar patients was offered by Sagoo
et al. [3], and a comprehensive survey was done by Shaf-
fer and Bejjani [4]. As to acquired chromosome anoma-
lies in malignancies, the efficiency of a-CGH allowed to
define the detection of putative oncogenes in the gained
regions of chromosome 20q, involved in the progression
of colorectal adenoma to carcinoma [5], or to demon-
strate a prognostic value of the gain of chromosome
regions in 1q and 16q in head and neck squamous cell
carcinoma [6]. This technique detected novel cryptic
copy number aberrations in the bone marrow (BM) of
15% patients with acute myeloid leukaemia (AML) and
with an apparent normal karyotype [7], whereas in other
cohort of patients it was instrumental in defining differ-
ent and complex chromosome changes [8,9]. A review
of the results in haematological malignancies obtained
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by a-CGH and single nucleotide polymorphism (SNP)
arrays is offered by Maciejewski et al. [10]. The use of
a-CGH permitted also to identify individuals predis-
posed to malignancy having constitutional deletions or
duplications of specific tumor suppressor genes [11].
A problem seldom faced is the definition of the sensi-
tivity of a-CGH to detect chromosome imbalances when
the DNA is extracted from a cell pool containing cells
with normal karyotype and cells with an unbalanced
anomaly. The data available in the literature on constitu-
tional mosaicism demonstrate that a-CGH may allow the
detection even of low grades of mosaicism [1]; Ballif et al.
[12] tried to estimate the detectable percentage of an
abnormal clone by mixing blood cells from a normal
diploid male with a trisomic 21 male, while Cheung et al.
[13] suggested a formula to infer the percentage of
mosaicism from a-CGH results, and assessed the possibi-
lity to detect proportions of abnormal cells around 7-8%.
All these authors used BAC-based arrays differently
designed. In their effort to compare the results which
may be obtained by means of BAC- and oligonucleotide-
based a-CGH, Neill et al. [14] conclude that mosaicisms
of 30% or greater may be easily detected with both meth-
ods, and that levels as low as 10% may also be detected,
but only under optimal conditions; they claim that BAC-
based arrays may be more sensible to reveal mosaicism
and in their study three cases with a level of mosaicism
of 10% were detected with BAC-based platforms, while
the lowest level of mosaicism detected with oligo array
was 21%. In their paper on haematological malignancies,
Maciejewski et al. [10] suggest a sensitivity of 25% abnor-
mal cells for their SNP-array system and a probable simi-
lar sensitivity for a-CGH.
The problem of the sensitivity is even more relevant in
the analysis of acquired mosaicism, that is the situation
in which cells carrying acquired imbalances coexist with
normal cells. In AML, 22 out of 26 cases with normal
karyotype were confirmed to be normal also by a-CGH,
but these results did not take into account at all the
sensitivity in detecting cryptic anomalies [7]. This point
is particularly relevant when the proportion of abnormal
cells is expected to be low, as in some cases of myelo-
dysplastic syndrome (MDS) [9,15], in chronic myelopro-
liferative disorder, in monitoring minimal residual
disease (MRD), or in acquired clonal anomalies in the
BM of non-malignant diseases, as Shwachman-Diamond
syndrome (SDS) [16].
To asses the real sensitivity of oligo-based a-CGH
platforms to detect mosaicism, we report here the
results of an experimental approach based on the in
vitro construction of DNA pools with precise percen-
tages of DNA from cells carrying well characterized
unbalanced chromosomal anomalies, mixed with DNA
from cells with normal karyotype.
Materials and methods
Patient samples
The material for the present study was offered by three
patients with constitutional unbalanced chromosome
anomalies revealed by QFQ-banding and fluorescent in
situ hybridization (FISH):
Patient 1, male newborn, with microcephaly and other
congenital anomalies, with a deletion of the long arms
of chromosome 7: the karyotype was 46,XY,del(7)(q34);
fibroblasts were supplied by the NIMGS Human Genetic
Cell Repository at the Coriell Institute for Medical
Research (Camden, NJ, USA);
Patient 2, 20-month-old female, with psychomotor
delay, facial dysmorphisms, hypotonia, bilateral pes val-
gus, with a deletion of the long arms of chromosome 4:
karyotype 46,XX,del(4)(q34.2); a lymphoblastoid cell line
was used;
Patient 3, 7-year-old female, with congenital thrombo-
cytopenia, with a pericentric inversion of chromosome
21; FISH with informative fosmid probes showed that
the rearrangement was more complex, with disruption
of RUNX1 gene and duplication of part of it including
exons 5; peripheral blood cells were used.
Informed consent to this study was obtained accord-
ing to the principles of the Declaration of Helsinki from
patients’ parents.
Methods
The chromosome imbalances present in the patients
were better defined by a-CGH with the whole-genome
platform 244 K (Agilent Technologies, Santa Clara, CA,
USA) according to the manufactory instructions (V 5.0).
DNA extraction was done using the Qiagen Blood ad
Tissue kit (QIAGEN GmbH, Hilden, Germany) and
competitor DNA was purchased from Promega (Pro-
mega Corporation, Madison, WI, USA). Slides were
scanned using Agilent’s microarray scanner G2565BA
and features were extracted by Agilent’s Feature Extrac-
tion 9.5.1 software. The a-CGH profiles of patients were
extrapolated by the Agilent’s Genomic Workbench soft-
ware (5.0.14), and are shown in Figures 1, 2, 3A, 4. The
base pair designations from the Agilent 244 K array are
according to the March 2006 Assembly (NCBI36/hg18)
on the UCSC Human Genome browser http://genome.
ucsc.edu/. In patient 1 the deletion of chromosome 7
was in fact terminal, with the loss of 14.164 Mb, starting
at 144,657,114 bp position within the band q35 (Figure
1A). In patient 2 the a-CGH showed the terminal dele-
tion of chromosome 4 with breakpoint in the band
q34.2 with loss of 14.39 Mb, starting at 176,883,225 bp
position (Figure 2A), but also that part of the terminal
region of the short arms of chromosome 9 was dupli-
cated, corresponding to a segment of 5.401 Mb (p24.1-
pter), with duplication starting at 5,554,309 bp position
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(Figure 3A). To investigate the localization of the extra
material of chromosome 9, a dual colour FISH with two
BAC probes flanking the band 9p24.1 was performed
and the hybridization signals showed that the extra
material of chromosome 9 was transposed onto the
band q34.2 of the rearranged chromosome 4, giving evi-
dence that the anomaly was in fact an unbalanced trans-
location. The a-CGH results in patient 3 showed that
the complex rearrangement of chromosome 21 led to
four regions of imbalance of chromosome 21 (Figure 4):
a 36.1 Kb duplication of part of the RUNX1 gene in
band 22.12 (35138169-35174269 bp), a 38 Kb duplica-
tion of a segment in band 22.2 (39669148-39707107 bp),
a 1.393 Mb deletion in band 22.3 (43014727-44408507
bp), and a 162 Kb duplication again in band 22.3
(46493951-46656014 bp), being the last a benign copy
number variation (CNV), according to the Database of
Genomic Variants, updated March 2010 [17]. So, in
total, seven different unbalanced regions of different size
were present in the DNA of the three patients.
We then constructed a synthetic mosaicism by mixing
our patients’ DNA with the same normal sex-matched
DNA used as competitor. DNA concentrations (patients
and reference) were first estimated by using Invitrogen’s
QBit fluorimeter (Invitrogen Corporation, Carlsbad, CA,
USA) to obtain an absolute quantification of the sam-
ples. Then the precise relative molar ratio of the sam-
ples was assessed using Applied Biosystem’s RNaseP
(Applied Biosystem Corporation, Carlsbad, CA, USA)
quantitative real-time PCR assay as described previously
Figure 1 a-CGH partial profiles of chromosome 7 in patient 1. A) Patient’s 100% DNA. B) Synthetic mosaicism at 10% level, C) 8%, D) 7%.
Figure 2 a-CGH partial profiles of chromosome 4 in patient 2. A) Patient’s 100% DNA. B) Synthetic mosaicism at 10% level, C) 8%, D) 7%.
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[18]. The calculated molar ratio between patient’s DNA
and the normal reference DNA was then used to bring
all the samples to the same molar ratio. Dilutions to
obtain the synthetic mosaicism were prepared at 5%,
6%, 7%, 8%, 10% and 15% of the three patients’ DNA in
the reference sex-matched DNA.
The a-CGH assays on pooled DNA were performed
on customized slides 4 × 44 K (Agilent) and they were
carried on as detailed above. Customized arrays were
designed to cover the regions of interest of chromo-
somes 7, 4, 9, and 21, using Agilent’s e-array 5.0 soft-
ware http://earray.chem.agilent.com/, and other probes
mapping on different chromosomes as internal control:
the design format 4 × 44 K includes 43,100 selected
probes, and 2,118 standard Agilent’s control probes. The
slides used had a spatial resolution (average probe spa-
cing) of 9-10 Kb, similar to that of the customary
whole-genome platform 244 K. For patient 3 also
another different enriched customized slide was
designed with all the probes available from the Agilent’s
HD probe catalogue (0.7-1 Kb resolution) for the three
regions of subtle duplication on chromosome 21.
Results
The a-CGH results obtained on the mixed DNA pools,
mimicking acquired low grade mosaicism of 5, 6, 7, 8,
10, 15% level, showed the possibility to detect 15%
mosaicism of six out of seven imbalances tested, exclud-
ing the 32 Kb duplication in the long arms of chromo-
some 21 of patient 3. In no case 5% and 6% mosaicism
was clearly discernible. The profiles of the chromosome
7, 4, and 9 of mosaicism at levels 7, 8, and 10% in
patients 1 and 2 are illustrated in Figures 1, 2, 3 (panels
B, C, D): the analysis system was able to detect these
three imbalances at 8 and 10% level, and not at 7%.
In patient 3, with more subtle imbalances, the results
were different, depending on the fact that the imbalance
is a deletion or a duplication, on its size, and on the
number of oligomers covering the region involved. The
a-CGH with the customized slide mimicking the 244 K
resolution failed to reveal all the imbalances on chromo-
some 21 in diluted samples, while the customized slide
enriched in probes at a resolution of 0.7-1 Kb showed:
the 32 Kb duplication of part of the RUNX1 gene in
band 22.12 was not detected, even at 15% level, the 34.4
Kb duplication in band 22.2 was detected at 10 and 8%,
the 1.4 Mb deletion in band 22.3 was discerned at 10%,
but not at 8%, and the 150.9 Kb duplication in band
22.3 was noticed both at 10 and 8% (Figure 5A, B).
Discussion
The ability of a-CGH to detect reliably chromosome
imbalances in mosaicism was not yet well established
[14]. So, the goal of the present work was very practical:
to assess the sensitivity of one of the most used oligo-
mer-based a-CGH system to detect acquired (as well as
constitutional) low level mosaicism. In particular, most
recurrent unbalanced anomalies in MDS/AML and in
disorders predisposing to MDS/AML have a size com-
parable to those of our patients 1 and 2 [19], and a-
CGH may be used to monitor the abnormal clone dur-
ing the disease course, and to detect MRD. Altogether
our results demonstrate clearly the possibility to detect
Figure 3 a-CGH partial profiles of chromosome 9 in patient 2. A) Patient’s 100% DNA. B) Synthetic mosaicism at 10% level, C) 8%, D) 7%.
Figure 4 a-CGH partial profile of chromosome 21 in patient 3.
The regions of imbalance in 21q of patient’s 100% DNA.
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as low as 8% abnormal cells, at least for imbalances
involving regions of a sufficiently great size, as those of
patients 1 and 2. Obviously, more sensitive techniques
are available to monitor unbalanced chromosome
anomalies already identified [18,20]: our aim was not to
suggest a finer method to detect them, but a solid eva-
luation of a-CGH sensitivity is needed to draw correct
conclusions when it is used to study cohorts of patients
with disorders associated with acquired chromosome
anomalies, as AML [7-9], MDS [8,9,15], or diseases pre-
disposing to MDS/AML, as Shwachman-Diamond syn-
drome (SDS) [16].
A technical point deserves a comment: the possibility
to reach a correct result is related to the parameters of
DNA quality and to the choice of an informative plat-
form: the use of customized slides should be related to
the size of the region involved and it may be necessary
to design enriched slides with higher resolution probe
density for the region of interest, as we did in patient 3.
In patients 1 and 2 we were able to get easily evidence
of the abnormal cell population at 10 and 8% levels of
mosaicism (Figures 1, 2, 3), because we had already
defined the presence of the imbalance. In our material
the mosaicism was built up artificially, but in general in
patients in which the imbalance may be suspected from
the results of a-CGH at levels comparable to those here
presented, the tool to reach a conclusion is FISH with
informative probes, possibly on interphase nuclei, which
will be able to confirm or deny the presence of the
acquired mosaicism. This comparison of a-CGH and
FISH results is essential to draw definite conclusions, in
particular, in case of imbalances of smaller size, where
we showed that the sensitivity of a-CGH to give evi-
dence of a small population of abnormal cells is more
variable (results in patient 3) with potentially aberrant
regions more difficult to be revealed: a-CGH results
may in fact be really significant, and they have to be
more accurately investigated. So, we suggest that when-
ever a-CGH indicates a possible mosaicism which may
be evaluated 8-10%, as in our diluted material, FISH is
crucial.
A good example of the capacity of a-CGH to detect an
unexpected acquired mosaicism is offered by a patient
with SDS reported in 2006 [21], who was known to
have a clone with an acquired chromosome anomaly in
BM, namely an isochromosome for the long arms of
chromosome 7, i(7)(q10). This anomaly may be related
to the risk to develop MDS/AML [16], as a deletion of
the long arms of chromosome 20, del(20)(q11), another
frequent change found. In the follow-up, a-CGH
showed, besides the i(7)(q10), an interstitial deletion of
the long arms of chromosome 20 spanning 4.116 Mb in
bands q11.21-q11.23. The resolution of standard chro-
mosome analysis was insufficient to show the deletion,
but FISH with the BAC probe CTD-3092L7, mapping
within the deleted region, confirmed its presence in 30/
170 mitoses (17.6%), and 68/470 nuclei (14.5%) (unpub-
lished data).
Figure 5 a-CGH partial profiles of chromosome 21 in patient 3 at different levels of synthetic mosaicism. A) 10%, B) 8%.
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We explored also the possibility to infer the percen-
tage of abnormal cells found in acquired mosaics by a-
CGH, at least approximately. A formula derived by the
ADM2 algorithm used in the analytical software permits
such a calculation, and, for instance, when we applied it
to a-CGH results obtained in the patient with SDS
described above, led to evaluate the cell population with
the deletion of chromosome 20 to be 18.2% of BM cells
[22]. This evaluation agrees fairly well with the propor-
tion of abnormal cells evaluated by FISH.
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